Research Paper Volume 15, Issue 11 pp 5190—5214
Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection
Figure 4. Identification of potential immune subtypes of ccRCC patients and molecular characteristics. (A) PCA of ccRCC patients in TCGA cohort. (B) Heatmap of immune-related genes of C1/C2 ccRCC patients. (C, D) Kaplan-Meier curves showing overall survival (OS) of ccRCC immune subtypes in TCGA and ICGC cohorts. (E) TMB and number of mutated genes in C1/C2 ccRCC patients. (F, G) NAL and CIN score of C1/C2 ccRCC patients. (H, I) Expression of ICP genes in C1/C2 ccRCC patients from TCGA cohort and ICGC cohort separately. (J, K) Expression of ICD factors in C1/C2 ccRCC patients from TCGA cohort and ICGC cohort separately. (L, M) Expression of NMD factors in C1/C2 ccRCC patients from TCGA cohort and ICGC cohort separately. *padj < 0.05; **padj < 0.01; ***padj < 0.001.